Health TrialsbyHealthPanel

Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19

ConditionLong COVID Fatigue
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Calgary

About this trial

Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM). This trial aims to explore the efficacy of creatine monohydrate in managing PEM

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Experiencing symptoms at least 3 months after a COVID-19 diagnosis confirmed by positive polymerase chain reaction (PCR) test

Experiencing post-exertional malaise, as per the DePaul Symptom Questionnaire

Disqualifiers

Allergy or intolerance to creatine monohydrate or maltodextrin

Supplemented with creatine in the past eight weeks

orthopaedic injury or condition that would prevent exercise testing

change in medication related to Long COVID symptom management in the past month.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Creatine monohydrate

    Dietary supplement

    8 g/day creatine monohydrate powder

Treatment groups

24 Participants
are divided into 2 treatment groups
Group A: Creatine monohydrateExperimental treatment 1 intervention
Group B: MaltodextrinPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Oxygen consumption at ventilatory threshold

point of respiratory compensation point (i.e., ventilatory threshold 2) as a percent of maximal oxygen consumption

Time frame
From enrollment to the end of intervention at 8 weeks
2

Heart rate at ventilatory threshold

heart rate (in bpm) at point of ventilatory threshold

Time frame
From enrollment to the end of intervention at 8 weeks

Secondary outcomes

1

Fatigue

severity assessed using visual analog scale with zero being not present and 100 being the worst imaginable

Time frame
From baseline to mid intervention (4 weeks) to the end of the intervention (8 weeks)
2

Brain fog

severity assessed using visual analog scale with zero being not present and 100 being the worst imaginable

Time frame
From baseline to mid intervention (4 weeks) to post intervention (8 weeks)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Calgary

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: